Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach
The investment underscores Zynext Ventures' commitment to advancing innovation in critical therapeutic areas.
PENNINGTON, N.J., June 3, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US-based immuno-oncology company developing next-generation therapeutics for high-unmet need cancers.
Agenus' lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.
"Our investment in Agenus aligns perfectly with our vision to advance life-changing therapies and offer novel solutions anchored on science, innovation and health to empower patients," said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences. "Our extensive global partner network will also play a key role in supporting Agenus' entry into new indications and geographies, allowing these innovative therapies to reach more patients, faster. This collaboration will help propel Agenus' programmes and unlock their full potential."
In addition to capital, Zynext Ventures will bring deep expertise in data analytics and access to a broad global network of biotech, regulatory, and clinical partners. This synergistic approach aims to unlock new avenues for Agenus, enabling the company to broaden the application of its BOT/BAL programme into earlier lines of treatment and address a wider spectrum of cancers with significant unmet medical needs.
Dr. Garo Armen, Chairman and CEO of Agenus, said, "We are delighted to partner with Zynext Ventures in a truly synergistic relationship. BOT/BAL's remarkable results across nine distinct cancers, in both late-stage and neoadjuvant settings, inspire us to push the boundaries of what is possible in oncology. Zydus' commercial reach and expertise make them an ideal partner to accelerate the delivery of this potentially transformative therapy."
About Zynext Ventures
Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients.
About Zydus
Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.
For more details visit: www.zyduslife.com.
LinkedIn: @Zydusuniverse
Instagram: @ZydusUniverse
About Agenus
Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients.
For more details visit: www.agenusbio.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the planned collaboration, the development and commercialization of BOT/BAL, and anticipated timelines. Actual results may differ due to various risks and uncertainties, including regulatory approvals and other factors. Readers are encouraged to review each company's public filings for additional information regarding potential risks and timelines.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
an hour ago
- The Market Online
Gold Report: Why junior miners are back in vogue
In episode 12 of Contributors Corner, Stockhouse's Lyndsay Malchuk interviews Paul Sun, chief executive officer of Eminent Gold (TSXV:EMNT), a junior miner in Nevada, about the growing trend of major miners increasing reserves through junior acquisitions. Click here for the full story. This content has been prepared as part of a partnership with Globex Mining Enterprises Inc., Eminent Gold Corp., Centerra Gold Inc., Midland Exploration Inc., ElDorado Gold Corp. and Amex Exploration Inc., and is intended for informational purposes only. By the ounce At the time of writing on Tuesday, the price of gold was US$3,441.10, down from US$3,345.90 per ounce in our July 16 report, according to data from The Globe and Mail, with increasing long positions, junior market sentiment and US inflation supporting World Gold Council's thesis for higher prices. This week in gold Globex Mining Enterprises (TSX:GMX) continues to deliver value-accretive developments from its polymetallic 258-asset portfolio, with numerous recent milestones at properties with established resources de-risking the case for an investment. Junior miner Midland Exploration (TSXV:MD) announced a C$5,058,750 financing, through which Centerra Gold (TSX:CG), one of Canada's top gold miners, intends to take a 9.9 per cent position. Striking a similar note, Quebec junior gold miner Amex Exploration (TSXV:AMX) will undertake an up to C$30 million financing, including a C$17.6 million investment from Eldorado Gold (TSX:ELD), a gold and base metals producer that generated 520,000 ounces of gold in 2024, granting it a 17 per cent stake in Amex on an undiluted basis. Top trending gold stocks Join the discussion: Find out what everybody's saying about the junior and major mining stocks in this week's gold report on Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Toronto Star
an hour ago
- Toronto Star
Metrolinx laid off customer service workers days before using AI after Coldplay concert
Three former employees confirmed that the layoffs of more than 40 workers of the Ontario-based GO Contact Centre, GO Train's front-line customer service centre, was completed the week of July 7. The part-time permanent Contact Centre employees spoke to the Star on condition of anonymity because they have not yet received their severance packages.
Globe and Mail
an hour ago
- Globe and Mail
Dairy's outsized political influence and the trade war
Earlier this month, U.S. President Donald Trump threatened to impose 35-per-cent tariffs on imports from Canada starting on Aug. 1. And when it comes to trade negotiations, Canadian dairy – and the supply management system that oversees the industry – is treated like a 'sacred cow.' Trump has repeatedly aired frustrations over U.S. dairy farmers' limited access to Canada's market. Despite this, Ottawa has continued to make efforts to protect the industry from trade negotiations – even while Prime Minister Mark Carney makes other concessions. The Globe's agriculture and food policy reporter, Kate Helmore, joins the show to explain how supply management works, why it makes negotiating trade deals around dairy so challenging, and just how much political sway the dairy industry has. Questions? Comments? Ideas? Email us at thedecibel@
